Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types. Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
Company type
Dr Mike Fisher
Commercial Director 

One Nucleus

Meet One Nucleus at the UK Pavilion

OxStem Limited

Company type
Dr Carolyn Porter
Chief Business Officer 
Dr Stuart Collinson